Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I–IV colorectal cancer
Therapeutic Advances in Medical Oncology · 2024-01 · 16
DOI: 10.1177/17588359231220607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 27.01.2024. Verfasst von Wenhua Fan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, China, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Circulating tumor DNA (ctDNA) has emerged as a biomarker that can define the risk of recurrence after curative-intent surgery for patients with colorectal cancer (CRC). However, beyond the predictive power of postoperative ctDNA detection, the efficacy and potential limitations of ctDNA detection urgently need to be fully elucidated in a large cohort of CRC.
Objectives
To define potentially cured CRC patients through ctDNA monitoring following surgery.
Design
A prospective, multicenter, observational study.
Methods
We enrolled 309 patients with stages I–IV CRC who underwent definitive surgery. Tumor tissues were sequenced by a custom-designed next-generation sequencing panel to identify somatic mutations. Plasma was analyzed using a ctDNA-based molecular residual disease (MRD) assay which integrated tumor-genotype-informed and tumor-genotype-naïve ctDNA analysis. The turnaround time of the assay was 10–14 days.
Results
Postoperative ctDNA was detected in 5.4%, 13.8%, 15%, and 30% of patients with stage I, II, III, and IV disease, respectively, and in 17.5% of all longitudinal samples. Patients with positive postsurgery MRD had a higher recurrence rate than those with negative postsurgery MRD [hazard ratio (HR), 13.17; p < 0.0001], producing a sensitivity of 64.6%, a specificity of 94.8%, a positive predictive value (PPV) of 75.6%, and a negative predictive value (NPV) of 91.5%. Furthermore, patients with positive longitudinal MRD also had a significantly higher recurrence rate (HR, 14.44; p < 0.0001), with increased sensitivity (75.0%), specificity (94.9%), PPV (79.6%), and NPV (93.4%). Subgroup analyses revealed that adjuvant therapy did not confer superior survival for patients with undetectable or detectable MRD. In addition, MRD detection was less effective in identifying lung-only and peritoneal metastases.
Conclusion
Postoperative ctDNA status is a strong predictor of recurrence independent of stage and microsatellite instability status. Longitudinal undetectable MRD could be used to define the potentially cured population in CRC patients undergoing curative-intent surgery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department of Colorectal & Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Geneplus-Beijing, Beijing, China.
- Department of General Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
- Department of General Surgery, The First Affiliated Hospital of Shantou University Medical College, No. 57 Changping Road, Jinping District, Shantou, Guangdong 515041, China.
ORCID-Profile: Fang Li
Förderung
- Natural Science Foundation of Guangdong Province, China
- National Natural Science Foundation of China
Zitieren
APA
Fan, W., Xia, Z., Chen, R., Lin, D., Li, F., Zheng, Y., Luo, J., Xiong, Y., Yu, P., Gao, W., Gong, Y., Zhang, F., Zhang, S., & Li, L. (2024). Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I–IV colorectal cancer. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359231220607
Vancouver
Fan W, Xia Z, Chen R, Lin D, Li F, Zheng Y, et al. Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I–IV colorectal cancer. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359231220607
BibTeX
@article{Fan2024,
author = {Fan, Wenhua and Xia, Zhiyuan and Chen, Rongrong and Lin, Dagui and Li, Fang and Zheng, Yang and Luo, Jiongyong and Xiong, Yuanyuan and Yu, Pengli and Gao, Wei and Gong, Yuhua and Zhang, Feiran and Zhang, Sen and Li, Liren},
title = {Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I–IV colorectal cancer},
journal = {Therapeutic Advances in Medical Oncology},
year = {2024},
volume = {16},
doi = {10.1177/17588359231220607}
}
EUVIMED